Sarepta Therapeutics Inc (SRPT)
Quick ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 1,103,010 | 428,430 | 966,777 | 2,115,870 | 1,502,650 |
| Short-term investments | US$ in thousands | 251,782 | 1,247,820 | 1,022,600 | 0 | 435,923 |
| Receivables | US$ in thousands | — | — | — | — | — |
| Total current liabilities | US$ in thousands | 731,684 | 653,659 | 619,604 | 452,733 | 416,026 |
| Quick ratio | 1.85 | 2.56 | 3.21 | 4.67 | 4.66 |
December 31, 2024 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($1,103,010K
+ $251,782K
+ $—K)
÷ $731,684K
= 1.85
The quick ratio of Sarepta Therapeutics Inc has shown a consistent and strong liquidity position over the years indicated in the data. The quick ratio, which measures the company's ability to meet its short-term obligations with its most liquid assets, improved from 4.66 in December 2020 to 4.67 in December 2021, reflecting a slight increase in liquidity. However, there was a notable decrease in the quick ratio to 3.21 in December 2022 and a further decline to 2.56 in December 2023, indicating a potential strain on the company's short-term liquidity position.
The downward trend continued with a quick ratio of 1.85 in December 2024, signaling a significant reduction in the ability to cover immediate liabilities with readily available assets. This decline may raise concerns about the company's ability to meet its short-term financial obligations. Overall, the quick ratio analysis suggests that Sarepta Therapeutics Inc experienced a deterioration in its liquidity position over the years, warranting further investigation into the company's financial health and management of working capital.
Peer comparison
Dec 31, 2024